<div id="readability-page-1"><p>Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) have been assigned an average recommendation of &#34;Moderate Buy&#34; from the ten analysts that are  covering the stock, MarketBeat.com reports. One research analyst  has rated the stock with a sell recommendation, eight have given a buy recommendation and one  has issued  a strong buy recommendation on  the company. The average 1-year target price among brokers that have covered the stock in the last year is $50.6667.</p><div><p><span></span><span>Get <strong>Oruka Therapeutics</strong> alerts:</span></p></div><p>ORKA has been the subject of a number of research analyst reports. BTIG Research boosted their price target on Oruka Therapeutics from $63.00 to $73.00 and gave the company a &#34;buy&#34; rating in a report on Monday, January 12th. Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of Oruka Therapeutics in a research note on Thursday, January 22nd. HC Wainwright reduced their price target on shares of Oruka Therapeutics from $45.00 to $40.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, October 27th. Wedbush boosted their price objective on shares of Oruka Therapeutics from $42.00 to $45.00 and gave the company an &#34;outperform&#34; rating in a research report on Tuesday, January 13th. Finally, Jefferies Financial Group started coverage on shares of Oruka Therapeutics in a report on Thursday, November 13th. They issued a &#34;buy&#34; rating and a $45.00 target price on the stock.</p><p><b>Check Out Our Latest Stock Report on ORKA</b></p><h2>Insider Activity</h2><p>In related news, insider Joana Goncalves sold 7,000 shares of the business's stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $31.81, for a total transaction of $222,670.00. Following the completion of the transaction, the insider owned 1,518 shares in the company, valued at $48,287.58. The trade was a 82.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Company insiders own  24.69% of the company's stock. </p><h2>Hedge Funds Weigh In On Oruka Therapeutics</h2><p>Institutional investors have recently modified their holdings of the company. Legal &amp; General Group Plc bought a new stake in  Oruka Therapeutics in the 2nd quarter valued at about $28,000.  Ameritas Investment Partners Inc. bought a new stake in shares of  Oruka Therapeutics during the second quarter valued at approximately $31,000.  BNP Paribas Financial Markets boosted its position in shares of  Oruka Therapeutics by 464.0% during the second quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company's stock worth $31,000 after buying an additional 2,306 shares during the period.  PNC Financial Services Group Inc. bought a new position in  Oruka Therapeutics in the 3rd quarter worth approximately $39,000.  Finally, Russell Investments Group Ltd. acquired a new stake in  Oruka Therapeutics in the 3rd quarter valued at approximately $43,000. Institutional investors own  56.44% of the company's stock. </p><h2>Oruka Therapeutics Price Performance</h2><p>Shares of ORKA stock opened at $34.23 on Friday. The firm has a fifty day moving average of $30.93 and a two-hundred day moving average of $23.51. The firm has a market cap of $1.66 billion, a P/E ratio of -18.02 and a beta of -0.39. Oruka Therapeutics has a 1-year low of $5.49 and a 1-year high of $36.51. </p><p>Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.55) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.01.  On average, sell-side analysts expect that  Oruka Therapeutics will post -3.41 EPS for the current year. </p><h2>Oruka Therapeutics Company Profile</h2> (Get Free Report)<p>Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”  </p><p>The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than Oruka Therapeutics</li><li>Do not delete, read immediately</li><li>NEW LAW: Congress Approves Setup For Digital Dollar?</li><li>“Fed Proof” Your Bank Account with THESE 4 Simple Steps</li><li>A U.S. “birthright” claim worth trillions - activated quietly</li><li>The Crash Has Already Started (Most Just Don’t See It Yet)</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1JLQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T1JLQQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Oruka Therapeutics Right Now?</h2><p>Before you consider Oruka Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.</p><p>While Oruka Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Oruka Therapeutics, Inc. (NASDAQ:ORKA) has received an average analyst rating of "Moderate Buy" from ten analysts. The stock has one sell, eight buy, and one strong buy recommendation. The average target price is $50.67. Recent analyst reports include BTIG raising the price target to $73.00 and HC Wainwright lowering it to $40.00. Insider Joana Goncalves sold 7,000 shares at $31.81. Institutional investors own 56.44% of the company. ORKA opened at $34.23, with a market cap of $1.66 billion and a P/E ratio of -18.02. The company focuses on peptide-based therapies for oncology, with its lead candidate in Phase 1 trials.</p>

Market Beat

iShares US Pharma

iShares Global Healthcare

Invesco Nasdaq Biotechnology ETF

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

Oruka Therapeutics

VG Health

SPDR S&P Biotech

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

VanEck Biotech ETF

ALPS Medical Breakthrough

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Given Average Rating of "Moderate Buy" by Analysts